



## SOME CHEMICALS PRESENT IN INDUSTRIAL AND CONSUMER PRODUCTS, FOOD AND DRINKING-WATER

VOLUME 101

This publication represents the views and expert  
opinions of an IARC Working Group on the  
Evaluation of Carcinogenic Risks to Humans,  
which met in Lyon, 15-22 February 2011

LYON, FRANCE - 2013

IARC MONOGRAPHS  
ON THE EVALUATION  
OF CARCINOGENIC RISKS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER .....</b>	<b>1</b>
<b>LIST OF PARTICIPANTS .....</b>	<b>3</b>
<b>PREAMBLE.....</b>	<b>9</b>
A. GENERAL PRINCIPLES AND PROCEDURES .....	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review .....	11
4. Data for the <i>Monographs</i> .....	11
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION.....	14
1. Exposure data.....	15
2. Studies of cancer in humans .....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References .....	31
<b>GENERAL REMARKS .....</b>	<b>33</b>
<b>ANTHRAQUINONE.....</b>	<b>41</b>
1. Exposure Data .....	41
1.1 Chemical and physical data .....	41
1.2 Production and use.....	41
1.3 Occurrence and exposure .....	42
1.4 Regulations and guidelines .....	51
2. Cancer in Humans.....	51
2.1 Cohort and nested case-control studies .....	51
3. Cancer in Experimental Animals .....	57
3.1 Oral administration.....	57
4. Other Relevant Data .....	61

4.1 Absorption, distribution, metabolism, and excretion.....	61
4.2 Genetic and related effects.....	62
4.3 Mechanistic considerations.....	63
5. Summary of Data Reported.....	64
6. Evaluation.....	65
References.....	66
<b>1-AMINO-2,4-DIBROMOANTHRAQUINONE.....</b>	<b>71</b>
1. Exposure Data.....	71
1.1 Chemical and physical data.....	71
1.2 Production and use.....	72
1.3 Occurrence.....	72
1.4 Regulations and guidelines.....	72
2. Cancer in Humans.....	72
3. Cancer in Experimental Animals.....	73
3.1 Oral administration.....	73
4. Other Relevant Data.....	82
4.1 Absorption, distribution, metabolism, and excretion.....	82
4.2 Genetic and related effects.....	83
4.3 Other mechanistic considerations.....	85
5. Summary of Data Reported.....	86
6. Evaluation.....	86
References.....	87
<b>2-NITROTOLUENE.....</b>	<b>89</b>
1. Exposure Data.....	89
1.1 Chemical and physical data.....	89
1.2 Production and use.....	90
1.3 Occurrence.....	91
1.4 Regulations and guidelines.....	98
2. Cancer in Humans.....	99
2.1 Cohort studies.....	99
3. Cancer in Experimental Animals.....	100
3.1 Oral administration.....	100
4. Other Relevant Data.....	104
4.1 Absorption, distribution, metabolism and excretion.....	104
4.2 Genetic and related effects.....	106
4.3 Other mechanistic considerations.....	108
4.4 Susceptibility.....	109
4.5 Mechanisms of carcinogenesis.....	109
5. Summary of Data Reported.....	110
6. Evaluation.....	111
References.....	112

---

<b>DIETHANOLAMINE</b> .....	<b>117</b>
1. Exposure Data .....	117
1.1 Chemical and physical data .....	117
1.2 Production and use .....	118
1.3 Occurrence and exposure .....	120
1.4 Regulations and guidelines .....	122
2. Cancer in Humans .....	123
3. Cancer in Experimental Animals .....	126
3.1 Skin application .....	126
3.2 Genetically modified mouse .....	128
4. Other Relevant Data .....	128
4.1 Absorption, distribution, metabolism and excretion .....	128
4.2 Toxic effects .....	130
4.3 Genetic and related effects .....	130
4.4 Mechanistic data .....	131
4.5 Mechanisms of carcinogenesis .....	132
5. Summary of Data Reported .....	135
6. Evaluation .....	136
References .....	136
<b>COCONUT OIL DIETHANOLAMINE CONDENSATE</b> .....	<b>141</b>
1. Exposure Data .....	141
1.1 Chemical and physical data .....	141
1.2 Production and use .....	142
1.3 Occurrence .....	143
1.4 Regulations and guidelines .....	144
2. Cancer in Humans .....	144
3. Cancer in Experimental Animals .....	144
3.1 Skin application .....	144
4. Other Relevant Data .....	145
4.1 Absorption, distribution, metabolism, excretion .....	145
4.2 Genetic and related effects .....	146
4.3 Mechanisms of carcinogenesis .....	146
5. Summary of Data Reported .....	146
6. Evaluation .....	147
References .....	147
<b>DI(2-ETHYLHEXYL) PHTHALATE</b> .....	<b>149</b>
1. Exposure Data .....	149
1.1 Chemical and physical data .....	149
1.2 Production and use .....	150
1.3 Occurrence .....	152
1.4 Regulations and guidelines .....	174
2. Cancer in Humans .....	176
2.1 Studies specific for exposure to DEHP .....	176
2.2 Occupational exposure to phthalate plasticizers .....	177

3. Cancer in Experimental Animals .....	185
3.1 Inhalation .....	185
3.2 Oral administration .....	185
3.3 Intraperitoneal injection .....	190
3.4 Genetically modified mouse .....	190
3.5 Co-exposure with modifying agents .....	191
4. Other Relevant Data .....	192
4.1 Absorption, distribution, metabolism and excretion .....	192
4.2 Genetic and related effects .....	199
4.3 Mechanistic data .....	214
4.4 Susceptibility .....	251
4.5 Mechanistic considerations .....	253
5. Summary of Data Reported .....	257
6. Evaluation .....	260
References .....	260
<b>BENZOPHENONE .....</b>	<b>285</b>
1. Exposure Data .....	285
1.1 Chemical and physical data .....	285
1.2 Production and use .....	286
1.3 Occurrence .....	286
1.4 Regulations and guidelines .....	292
2. Cancer in Humans .....	293
3. Cancer in Experimental Animals .....	293
3.1 Oral administration .....	293
3.2 Dermal application .....	296
4. Other Relevant Data .....	296
4.1 Absorption and metabolism .....	296
4.2 Genetic and related effects .....	297
4.3 Toxic effects .....	297
4.4 Endocrine-disrupting effects .....	298
4.5 Mechanisms of carcinogenesis .....	299
5. Summary of Data Reported .....	300
6. Evaluation .....	301
References .....	301
<b>METHYL ISOBUTYL KETONE .....</b>	<b>305</b>
1. Exposure Data .....	305
1.1 Chemical and physical data .....	305
1.2 Production and use .....	306
1.3 Occurrence and exposure .....	306
1.4 Regulations and guidelines .....	309
2. Studies in Humans .....	309
3. Cancer in Experimental Animals .....	309
3.1 Inhalation .....	309
4. Other Relevant Data .....	312

---

4.1 Absorption, distribution, metabolism and excretion .....	312
4.2 Genetic and related effects.....	314
4.3 Toxic effects .....	314
4.4 Mechanistic considerations .....	316
5. Summary of Data Reported.....	319
6. Evaluation .....	321
References .....	321
<b>CUMENE .....</b>	<b>325</b>
1. Exposure Data .....	325
1.1 Chemical and physical data .....	325
1.2 Production and use.....	326
1.3 Occurrence .....	326
1.4 Human exposure .....	331
1.5 Regulations and guidelines .....	338
2. Cancer in Humans.....	338
3. Cancer in Experimental Animals .....	338
3.1 Inhalation exposure .....	338
3.2 Carcinogenicity of metabolites .....	343
4. Other Relevant Data .....	343
4.1 Absorption, distribution, metabolism and excretion .....	343
4.2 Genetic and related effects.....	344
4.3 Mechanistic data.....	345
4.4 Mechanisms of carcinogenesis .....	346
5. Summary of Data Reported.....	346
6. Evaluation .....	347
References .....	347
<b>3-MONOCHLORO-1,2-PROPANEDIOL.....</b>	<b>349</b>
1. Exposure Data .....	349
1.1 Chemical and physical data .....	349
1.2 Production and use.....	354
1.3 Occurrence .....	355
1.4 Regulations and guidelines .....	358
2. Cancer in Humans.....	359
3. Studies in Experimental Animals.....	359
3.1 Oral administration.....	359
3.2 Subcutaneous administration .....	362
3.3 Dermal application .....	362
4. Other Relevant Data .....	362
4.1 Absorption, distribution, metabolism and excretion .....	362
4.2 Genetic and related effects.....	363
4.3 Mechanistic considerations .....	363
4.4 Mechanisms of carcinogenesis .....	367
5. Summary of Data Reported.....	368
6. Evaluation .....	369
References .....	369

<b>1,3-DICHLORO-2-PROPANOL</b> .....	<b>375</b>
1. Exposure Data .....	375
1.1 Chemical and physical data .....	375
1.2 Production and use.....	376
1.3 Occurrence .....	378
1.4 Regulations and guidelines .....	379
2. Cancer in Humans.....	379
3. Cancer in Experimental Animals .....	379
3.1 Oral administration .....	379
4. Other Relevant Data .....	381
4.1 Absorption, distribution, metabolism, and excretion.....	381
4.2 Genetic and related effects.....	384
4.3 Mechanistic data.....	384
4.4 Mechanisms of carcinogenesis .....	386
5. Summary of Data Reported.....	386
6. Evaluation .....	387
References .....	387
<b>2,4-HEXADIENAL</b> .....	<b>391</b>
1. Exposure Data .....	391
1.1 Chemical and physical data .....	391
1.2 Production and use.....	392
1.3 Occurrence .....	392
1.4 Regulations and guidelines .....	396
2. Cancer in Humans.....	396
3. Cancer in Experimental Animals .....	396
3.1 Oral administration.....	396
4. Other Relevant Data .....	399
4.1 Absorption, distribution, metabolism, and excretion.....	399
4.2 Genetic and related effects.....	399
4.3 Mechanistic data.....	400
4.4 Mechanisms of carcinogenesis .....	401
5. Summary of Data Reported.....	401
6. Evaluation .....	402
References .....	402
<b>METHYLEUGENOL</b> .....	<b>407</b>
1. Exposure Data .....	407
1.1 Chemical and physical data .....	407
1.2 Production and use.....	408
1.3 Occurrence .....	409
1.4 Regulations and guidelines .....	416
2. Cancer in Humans.....	417
3. Cancer in Experimental Animals .....	417
3.1 Oral administration .....	417
3.2 Intraperitoneal injection .....	421
3.3 Carcinogenicity of metabolites .....	423



---

4. Other Relevant Data .....	423
4.1 Absorption, distribution, metabolism and excretion .....	423
4.2 Genetic and related effects.....	424
4.3 Mechanistic data.....	426
4.4 Susceptibility.....	427
4.5 Mechanisms of carcinogenesis .....	427
5. Summary of Data Reported.....	427
6. Evaluation .....	428
References .....	429
<b>2-METHYLIMIDAZOLE.....</b>	<b>435</b>
1. Exposure Data .....	435
1.1 Chemical and physical data .....	435
1.2 Production and use.....	436
1.3 Occurrence .....	436
1.4 Regulations and guidelines .....	437
2. Cancer in Humans.....	437
3. Cancer in Experimental Animals .....	437
3.1 Oral administration .....	437
4. Other Relevant Data .....	440
4.1 Absorption, distribution, metabolism and excretion .....	440
4.2 Genetic and related effects.....	441
4.3 Mechanistic data.....	442
4.4 Mechanisms of carcinogenesis .....	442
5. Summary of Data Reported.....	443
6. Evaluation .....	444
References .....	444
<b>4-METHYLIMIDAZOLE.....</b>	<b>447</b>
1. Exposure Data .....	447
1.1 Chemical and physical data .....	447
1.2 Production and use.....	447
1.3 Occurrence .....	448
1.4 Regulations and guidelines .....	452
2. Cancer in Humans.....	452
3. Cancer in Experimental Animals .....	452
3.1 Oral administration .....	452
4. Other Relevant Data .....	454
4.1 Absorption, distribution, metabolism and excretion .....	454
4.2 Genetic and related effects.....	455
4.3 Mechanistic data.....	456
4.4 Mechanisms of carcinogenesis .....	456
5. Summary of Data Reported.....	456
6. Evaluation .....	457
References .....	457



<b>INTRODUCTION TO THE MONOGRAPHS ON BROMOCHLOROACETIC ACID, DIBROMOACETIC ACID AND DIBROMOACETONITRILE</b> .....	<b>461</b>
Cancer in Humans .....	462
1. Cohort studies .....	462
2. Case-control studies .....	475
3. Meta-analyses and pooled analyses .....	491
References .....	491
<b>BROMOCHLOROACETIC ACID</b> .....	<b>495</b>
1. Exposure Data .....	495
1.1 Chemical and physical data .....	495
1.2 Production and use .....	496
1.3 Occurrence and exposure .....	496
1.4 Regulations and guidelines .....	501
2. Cancer in Humans .....	501
3. Cancer in Experimental Animals .....	501
3.1 Oral administration .....	501
4. Other Relevant Data .....	504
4.1 Absorption, distribution, metabolism and excretion .....	504
4.2 Genetic and related effects .....	506
4.3 Mechanistic data .....	506
4.4 Susceptibility .....	506
4.5 Mechanisms of carcinogenesis .....	506
5. Summary of Data Reported .....	508
6. Evaluation .....	509
References .....	509
<b>DIBROMOACETIC ACID</b> .....	<b>513</b>
1. Exposure Data .....	513
1.1 Chemical and physical data .....	513
1.2 Production and use .....	514
1.3 Occurrence .....	514
1.4 Regulations and guidelines .....	519
2. Cancer in Humans .....	519
3. Cancer in Experimental Animals .....	519
3.1 Oral administration .....	519
4. Other Relevant Data .....	521
4.1 Absorption, distribution, metabolism and excretion .....	521
4.2 Genetic and related effects .....	523
4.3 Mechanistic data .....	527
4.4 Susceptibility .....	527
4.5 Mechanisms of carcinogenesis .....	527
5. Summary of Data Reported .....	528
6. Evaluation .....	529
References .....	529

---

<b>DIBROMOACETONITRILE.....</b>	<b>533</b>
1. Exposure Data .....	533
1.1 Chemical and physical data .....	533
1.2 Production and use.....	534
1.3 Occurrence and exposure .....	534
1.4 Regulations and guidelines .....	538
2. Cancer in Humans.....	538
3. Cancer in Experimental Animals .....	538
3.1 Oral administration.....	538
3.2 Skin application.....	541
3.3 Co-exposure with modifying agents.....	541
4. Other Relevant Data .....	541
4.1 Absorption, distribution, metabolism and excretion .....	541
4.2 Genetic and related effects.....	544
4.3 Mechanistic data.....	544
4.4 Susceptibility.....	546
4.5 Mechanisms of carcinogenesis .....	546
5. Summary of Data Reported.....	546
6. Evaluation .....	547
References .....	547
<b>LIST OF ABBREVIATIONS.....</b>	<b>551</b>
<b>CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS.....</b>	<b>555</b>



## NOTE TO THE READER

---

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

